876379-79-2

Basic information

• Product Name: 3-bromoH-pyrazolo[1,5-a]pyridine-5-carboxylic acid
• Synonyms: 3-bromoH-pyrazolo[1,5-a]pyridine-5-carboxylic acid;3-bromopyrazolo[1,5-a]pyridine-5-carboxylic acid;3-broMopyrazolo[1;5-a]pyridine-5-carboxylic acid;Pyrazolo[1,5-a]pyridine-5-carboxylicacid, 3-bromo-;EOS-61323
• CAS NO: 876379-79-2
• Molecular Formula: C₈H₅BrN₂O₂
• Molecular Weight: 241.05
• Product Categories: CHIRAL CHEMICALS
• Mol File: 876379-79-2.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Density: 1.89 g/cm³
• Refractive Index: 1.728
• PKA: 0.63±0.30(Predicted)
• CAS DataBase Reference: 3-bromoH-pyrazolo[1,5-a]pyridine-5-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromoH-pyrazolo[1,5-a]pyridine-5-carboxylic acid(876379-79-2)
• EPA Substance Registry System: 3-bromoH-pyrazolo[1,5-a]pyridine-5-carboxylic acid(876379-79-2)

Safety Data

• Hazardous Substances Data: 876379-79-2(Hazardous Substances Data)

Usage

Description

3-bromoH-pyrazolo[1,5-a]pyridine-5-carboxylic acid is a chemical compound that belongs to the class of pyrazolopyridines. It is characterized by the presence of a bromine atom at the 3-position and a carboxylic acid group at the 5-position. 3-bromoH-pyrazolo[1,5-a]pyridine-5-carboxylic acid has potential applications in various fields due to its unique chemical properties.

Uses

Used in Pharmaceutical Industry:
3-bromoH-pyrazolo[1,5-a]pyridine-5-carboxylic acid is used as a reagent in the preparation of pyrazolopyridines, which are a class of compounds with potential therapeutic applications. These pyrazolopyridines have been identified as inhibitors of Cryptosporidium parvum and Cryptosporidium hominis, two protozoan parasites that cause cryptosporidiosis, a diarrheal disease affecting humans and animals.
Used in Antimicrobial Applications:
3-bromoH-pyrazolo[1,5-a]pyridine-5-carboxylic acid is used as an antimicrobial agent for the development of potential drug candidates against cryptosporidiosis. 3-bromoH-pyrazolo[1,5-a]pyridine-5-carboxylic acid's ability to inhibit the growth of Cryptosporidium parvum and Cryptosporidium hominis makes it a promising candidate for the treatment of this disease, which can be particularly severe in immunocompromised individuals.

InChI:InChI=1/C8H5BrN2O2/c9-6-4-10-11-2-1-5(8(12)13)3-7(6)11/h1-4H,(H,12,13)

Upstream product

• 2459-09-8 4-pyridinecarboxylic acid, methyl ester 
• 1101120-00-6 3-ethyl 5-methyl pyrazolo[1,5-a]pyridine-3,5-dicarboxylate 
• 104468-87-3 pyrazolo [1,5-a]pyridine-5-carboxylic acid 
• 1610611-84-1 methyl 3-bromopyrazolo[1,5-a]pyridine-5-carboxylate 

Downstream Products

• 1610611-38-5 N-(5-cyanopyridin-2-yl)-N-cyclopropyl-3-(4-(cyclopropylcarbamoyl)phenyl)pyrazolo[1,5-a] pyridine-5-carboxamide 
• 1610611-55-6 N-(5-cyanopyridin-2-yl)-N-ethyl-3-(4-[N-methylsulfamoyl]phenyl)pyrazolo[1,5-a]pyridine-5-carboxamide 
• 1610611-56-7 N-(4-cyanophenyl)-N-cyclopropyl-3-(5-(methylcarbamoyl)pyridin-2-yl)pyrazolo[1,5-a]pyridine-5-carboxamide 
• 1610611-57-8 3-(5-carbamoylpyridin-2-yl)-N-(4-cyanophenyl)-N-cyclopropylpyrazolo[1,5-a]pyridine-5-carboxamide 
• 1610611-85-2 3-bromo-N-(4-cyanophenyl)-N-methylpyrazolo[1,5-a]pyridine-5-carboxamide 
• 1610611-90-9 3-bromo-N-(4-fluorophenyl)-N-methyl pyrazolo[1,5-a]pyridine-5-carboxamide 
• 1610612-35-5 C₃₀H₃₀N₆O₄ 
• 1610610-33-7 N-(4-cyanophenyl)-N-methyl-3-(1-methyl-1H-indazol-5-yl)pyrazolo[1,5-a]pyridine-5-carboxamide 
• 1610610-34-8 3-(6-acetamidopyridin-3-yl)-N-(4-cyanophenyl)-N-methylpyrazolo[1,5-a]pyridine-5-carboxamide 
• 1610610-36-0 3-(4-carbamoylphenyl)-N-(4-fluorophenyl)-N-methylpyrazolo[1,5-a]pyridine-5-carboxamide 
• 1610612-38-8 tert-butyl 2-(4-cyanophenyl)-1-methyl-2-(3-(6-(methylcarbamoyl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-5-carbonyl)hydrazinecarboxylate 
• 1610610-42-8 (S)-3-(4-(2-aminopropanamido)phenyl)-N-(4-cyanophenyl)-N-methylpyrazolo[1,5-a]pyridine-5-carboxamide 
• 1610612-58-2 3-bromo-N-(4-cyanophenyl)-N-cyclopropylpyrazolo[1,5-a]pyridine-5-carboxamide 
• 1610610-56-4 N-(4-cyanophenyl)-N-methyl-3-(1H-pyrrolo[2,3-b]pyridin-5-yl)pyrazolo[1,5-a]pyridine-5-carboxamide 

Relevant articles and documents

COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES

The present invention provides compounds of formula I: [INSERT FORMULA HERE] or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a Plasmodium parasite, such as malaria.